Dexcom (DXCM) is a publicly traded Healthcare sector company. As of May 20, 2026, DXCM trades at $71.03 with a market cap of $25.12B and a P/E ratio of 33.13. DXCM moved +6.60% today. Year to date, DXCM is +5.60%; over the trailing twelve months it is -18.20%. Its 52-week range spans $54.11 to $93.25. Analyst consensus is strong buy with an average price target of $80.10. Rallies surfaces DXCM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DXCM financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DXCM recently traded at $71.03. Market cap is $25.12B. P/E ratio is 33.13. Revenue is $4.66B.
| Metric | Value |
|---|---|
| Price | $71.03 |
| Market Cap | $25.12B |
| P/E Ratio | 33.13 |
| EPS | $2.14 |
| Dividend Yield | 0.00% |
| 52-Week High | $93.25 |
| 52-Week Low | $54.11 |
| Volume | 9.83M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.66B |
| Net Income | $836.30M |
| Gross Margin | 60.10% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.66B | $836.30M | $2.14 |
| 2024 | $4.03B | $576.20M | $1.46 |
| 2023 | $3.62B | $541.50M | $1.40 |
| 2022 | $2.91B | $341.20M | $0.88 |
21 analysts cover DXCM: 0 strong buy, 19 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $80.10.